Effect of hyperglycemia and neuropeptides on interleukin-8 expression and angiogenesis in dermal microvascular endothelial cells  by Jain, Monica et al.
BASIC RESEARCH STUDIES
Effect of hyperglycemia and neuropeptides on
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dermal microvascular endothelial cells
Monica Jain, BS, Frank W. LoGerfo, MD, Patrick Guthrie, BS, and Leena Pradhan, PhD, Boston, Mass
Background: Impaired wound healing is a major complication associated with diabetes, involving a dysregulation and
impairments in the inflammatory and angiogenic phases of wound healing. Here, we examine the effects of the neuropeptides
substance P (SP) and neuropeptide Y (NPY) on dermal microvascular endothelial cell (DMVEC) angiogenesis and interleu-
kin-8 (IL-8) expression, a known effector of the neuropeptide pathways in normal and hyperglycemic conditions in vitro.
Methods: DMVECs are treated with one of four glucose concentrations: 1) 5 mM glucose; 2) 10 mM glucose; 3) 30 mM
glucose; or 4) 30mMmannitol and cotreated with 100 nMNPY, 100 nMSP, or 10 ng/mL IL-8. Angiogenesis is assessed
with proliferation and tube formation assays. IL-8 mRNA and protein expression are evaluated at days 1 and 7.
Results: As compared with noromoglycemia (5 mM glucose), hyperglycemia (30 mM glucose) decreases DMVEC
proliferation and tube formation by 39% and 42%, respectively. SP cotreatment restores DMVEC proliferation (211%)
and tube formation (152%), and decreases IL-8 expression (34%) in DMVECs exposed to hyperglycemic conditions.
These effects are not observed with NPY. However, IL-8 treatment by itself does not affect proliferation or tube
formation, suggesting that the effect of SP on DMVEC angiogenesis is unlikely through changes in IL-8 expression.
Conclusion:Hyperglycemic conditions impair DMVEC proliferation and tube formation. SPmitigates the effect of hypergly-
cemia on DMVECs by increasing DMVEC proliferation and tube formation. These findings are not likely to be related to a
dysregulation of IL-8 due to the lack of effects of hyperglycemia on IL-8 expression and the lack of effect of IL-8 on DMVEC
proliferation and tube formation. The effect of SP onDMVECsmakes SP a promising potential target for therapy in impaired
wound healing in diabetes, but the exact mechanism remains unknown. (J Vasc Surg 2011;53:1654-60.)
Clinical Relevance: Chronic diabetic foot ulceration, as a result of impaired wound healing in diabetes, is the source of a
vast quantity of hospitalizations and lower extremity amputations across the nation. Normal wound healing involves the
bidirectional signaling and interaction between a multitude of inflammatory cytokines and neuropeptides, and previous
research has demonstrated a dysregulation in the expression and activity of these molecules in diabetes. This work
evaluates the effect of hyperglycemic conditions and neuropeptides on DMVECs, a cell type fundamental to the wound
healing process, but in which research is currently limited. The discovery of a molecule, which promotes angiogenesis in
hyperglycemic conditions would be a promising therapeutic target for impaired wound healing in diabetes. In addition,
the determination of the effects of these neuropeptides and cytokines on DMVECs could elucidate other potential
therapies, which could decrease wound-healing time and improve overall wound healing in other realms of medicine.
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diabetic foot ulceration (DFU), is a major complication
associated with both Type I and Type II diabetes that
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1654ignificantly impairs the quality of life of diabetic patients.
n particular, DFU is the leading complaint in all diabetic
ospitalizations, resulting in a rate increase of over 10-fold
f nontraumatic lower-extremity amputations in diabetic
ersus nondiabetic patients.1
Normal wound healing is a complex and precise process
hat consists of four phases: hemostasis, inflammation, pro-
iferation, and remodeling. The integration and well-timed,
inear progression through these phases, as well as the
ppropriate interaction between the cells and the inflamma-
ory cytokines, is necessary for proper wound healing.2
ost frequently implicated as alterations in both Type I
nd Type II diabetes and observed as the sources of im-
aired wound healing in diabetes are peripheral vascular
isease and peripheral sensory neuropathy.3 In diabetes,
here is a chronic upregulation of inflammatory cytokines.
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Volume 53, Number 6 Jain et al 1655In addition, current work in our laboratory demonstrates
that the initial acute inflammatory phase that leads to the
secretion of cytokines, chemokines, and growth factors
from immune cells is disrupted due to hyperglycemia,
leading to abnormal expression and activity of these essen-
tial inflammatory mediators in wound healing.4-6 Recent
studies have shown that in normal wound healing, the
neuromodulators interact with a variety of cell types in-
volved in wound repair and regulate cytokine expression
and activity, eliciting the downstream signaling of the in-
flammation and proliferation phases of wound healing.
Moreover, in diabetics, these neuropeptides are decreased.7
Therefore, a general impairment of the natural wound
healing process, due to the nonsynchronous and incom-
plete progression through the various phases of wound
healing, can be attributed to alterations in the interaction
between cytokines and neuropeptides.7-9
The neuropeptides and inflammatory cytokines com-
monly associated with the success of normal wound healing
and found to have abnormal expression in diabetic patients
include the neuropeptides, neuropeptide Y (NPY) and sub-
stance P (SP), and the cytokines, interleukin (IL)-6, IL-8,
tumor necrosis factor-, platelet-derived growth factor, fibro-
blast growth factor, vascular endothelial growth factor, trans-
forming growth factor (TGF)-, and TGF-.7,10,11 It is un-
known whether these neuropeptides influence the expression
of cytokines in endothelial cells and/or whether these neuro-
peptides act through those cytokines to regulate angiogenesis
and thus wound healing in hyperglycemic conditions.
IL-8 is a potent chemoattractant for keratinocytes, neu-
trophils, and other leukocytes, is a promoter of neutrophil
adhesion, and is a known and potent autocrine proangiogenic
molecule.7 IL-8 is also one of the key inflammatory cytokines
in wound healing that is chronically upregulated in diabetes
andwhose expression in the acute inflammatory phase follow-
ing injury in diabetic patients is disrupted.4,7 Moreover, SP is
known to increase the secretion of IL-8 from different cell
types, including colonic epithelial cells, airway epithelial cells,
and mesenteric adipocytes.12-14
The goal of this study is to investigate the role of IL-8
in the effects of NPY and SP on the dermal microvascular
endothelial cells (DMVECs) angiogenesis in normal and
hyperglycemic conditions.
METHODS
Cell culture. Primary DMVECs were obtained from
Lonza (Walkersville, Md) and grown in Lonza microvascu-
lar endothelial cell media (EGM-2MV). Cells were cul-
tured to passages between 4 and 8. For the proliferation,
mRNA expression, and protein expression assays, cells were
plated at a density of 10,000 cells/cm2; for the tube for-
mation assay, cells were plated according to the assay pro-
tocol. Cells were subjected to one of four different glucose
concentrations: 1) 5 mM glucose (standard EGM-2MV
media); 2) 10 mM glucose 10 mM (EGM-2MV  5 mM
D-glucose); 3) 30 mM glucose (EGM-2MV  25 mM
D-glucose); or 4) 30 mM mannitol (osmolarity control; aGM-2MV  25 mM mannitol). In addition, DMVECs
ere cotreated with 100 nM NPY (Sigma-Aldrich, St.
ouis, Mo) or 100 nM SP (Sigma-Aldrich).
Proliferation assay. DMVECs were plated in repli-
ates of six in 96-well plates. Twenty-four hours after
lating, DMVECs were treated as listed above. On days 1,
, 3, 5, and 7 after treatment, treatment media was aspi-
ated off, and cells were subjected to 200 L of 10% Alamar
lue (Trek Diagnostic Systems) in EGMmedia (Lonza) for
hours. Data were read at OD570 and OD600 and pre-
ented as OD relative to day 1, representing fold change,
s previously described.15
Tube formation assay. DMVECs were treated, as
isted above, and plated at a density of 20,000 cells/well, onto
he BD BioCoat Angiogenesis System – Endothelial Cell
ube Formation assay plate (BDBiosciences, Bedford,Mass).
fter 18 hours, the plates were washed twice with Hank’s
alanced Salt Solution (HBSS; Invitrogen, Carlsbad, Calif).
ells were then stained for 30minuteswith 8mg/mLCalcein
M (Invitrogen) in HBSS and were again washed twice with
BSS. Finally, plates were imaged using a Nikon Eclipse Ti
nverted fluorescent microscope (Melville, NY). Images were
nalyzed for total DMVEC tube fluorescence as a percentage
f the entire well area using National Institutes of Health
mageJ software (Bethesda, Md).
Quantitate reverse transcription polymerase chain
eaction (QRT-PCR). DMVECs were plated in tripli-
ates on 24-well plates. Twenty-four hours after plating,
MVECs were treated as listed above. Total RNA was
xtracted from the DMVECs using a Qiagen RNeasy Mini
it (Valencia, CA) at 24 hours and 7 days after treatment.
DNA was prepared from 10 ng of RNA using the Bio-Rad
Script cDNA synthesis kit (Hercules, Calif). IL-8 mRNA
evels were then quantified, using a Stratagene MX3000P
eal-time PCR machine (La Jolla, Calif) and the following
hermal cycling protocol: Stage 1: 10 minutes at 95°C – 1
ycle; Stage 2: 15 s at 95°C and 1 minute at 65°C, and 30 s
t 72°C – 40 cycles. Primers and probes from Integrated
NA Technologies (Coralville, Iowa), at concentrations of
00 nM, and Stratagene Brilliant QPCR Master Mix re-
gents were used. Target gene levels were normalized to
(2) -microglobulin (2M), as previously described.15 All
ontrol treatments were compared to the 5-mM glucose
ontrol treatment within day 1 or day 7, and NPY 100 nM
nd SP 100-nM treatments were compared with their
espective glucose control treatment within day 1 or day 7.
ata are presented as relative IL-8 mRNA level.
Enzyme-linked immunosorbent assay (ELISA).
ssay was performed on cell culture supernatants from the
RNA expression assay plates at 1 and 7 days after treat-
ent. A BCA Protein Assay (Thermo Scientific, Waltham,
ass) was performed to quantify total protein content. An
L-8 ELISA kit from R&D Systems (Minneapolis, Minn)
as used to quantify IL-8 protein levels. Plates were read
ith a Bio-Tek U-Quant Microplate Reader (Winooski,
t). IL-8 levels were standardized to total protein content,
nd data are presented as standardized IL-8 protein level.
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June 20111656 Jain et alStatistical analysis. All experiments were repeated at
least three times, and each treatment condition was per-
formed in at least triplicate. All data are presented as the
mean  standard deviation. Statistical analysis was per-
formed using GraphPad Prism software (La Jolla, Calif).
Significance of association was assessed using two-way anal-
ysis of variance (ANOVA) with Bonferroni post-hoc test or
one-way ANOVA with Bonferroni post-hoc test. P  .05
was considered to be statistically significant.
RESULTS
Hyperglycemia decreases DMVEC proliferation
and tube formation. As compared with the 5-mM glu-
cose control treatment, DMVECs treated with 10 mM and
30 mM glucose demonstrate statistically significant de-
creases in proliferation by day 7, (5 mM glucose [1.309 
0.523] vs 10 mM glucose [0.734  0.235] and 30 mM
glucose [0.802 0.219], n 3; P .001). No significant
differences in proliferation are observed between DMVECs
treated with 10 mM and 30 mM glucose (Fig 1, A).
Representative pictures of DMVECs treated with 5 mM
and 30mM glucose demonstrate decreases in tube formation
in DMVECs treated with 30 mM glucose (Fig 1, B).
As compared with the 5-mM glucose control treat-
ment, DMVECs treated with 30 mM glucose demonstrate
statistically significant decreases in tube formation (5 mM
glucose [4.245% 0.377%] vs 30 mM glucose [2.460%
0.365%], n  3; P  .001).
No significant differences in proliferation or tube for-
Fig 1. Effect of glucose on dermal microvascular endo
Effect of 5 mM, 10 mM, and 30 mM glucose on DMVE
as relative OD compared to day 1 for each treatme
Representative pictures of DMVEC tube formation upon
of DMVEC tube formation upon treatment with 5 mM
fluorescent tubes normalized to total well area (n  3, mmation are observed in DMVECs treated with 30 mM oannitol as compared with control glucose treatment (data
ot shown; Fig 1, C).
SP treatment restores DMVEC proliferation and
ube formation in cells exposed to hyperglycemia. As
ompared with DMVECs only treated with 10 mM or 30
M glucose, DMVECs cotreated with 100 nM SP dem-
nstrate statistically significant increases in proliferation (10
Mglucose [0.734 0.235] vs 10mMglucose 100 nM
P [1.388  0.258], n  3; P  .01; 30 mM glucose
0.802  0.219] vs 30 mM glucose  100 nM SP [1.708
0.546], n  3; P  .001; Fig 2, A).
As compared with DMVECs only treated with 30 mM
lucose, DMVECs cotreated with 100 nM SP demonstrate
tatistically significant increases in tube formation (30 mM
lucose [2.460%  0.365%] vs 30 mM glucose  100 nM
P [3.764%  1.354%], n  3; P  .05; Fig 2, B and
upplemental Fig 1, online only).
No significant differences in proliferation or tube for-
ation are observed between DMVECs cultured in 5 mM
lucose and cotreated with 100 nM SP versus the 5-mM
lucose control treatment (Fig 2, A and B).
NPY cotreatment does not affect DMVEC prolifer-
tion and tube formation. DMVECs cotreated with
00 nM NPY did not demonstrate any statistically sig-
ificant changes in proliferation (Fig 3, A) or tube
ormation (Fig 3, B and Supplemental Fig 1, online only)
t any glucose concentrations. However, a trend toward
ncreased tube formation with NPY cotreatment in both
he 5-mM glucose and 30-mM glucose concentrations is
al cell (DMVEC) proliferation and tube formation. A,
liferation at 1, 2, 3, 5, and 7 days. Data are represented
espectively (n  3, mean  SD; ***P  .001). B,
ment with 5 mM and 30 mM glucose.C,Quantification
30 mM glucose. Data are represented as area of intact
SD; ***P  .001).theli
C pro
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Volume 53, Number 6 Jain et al 1657SP treatment decreases while NPY treatment does
not affect DMVEC IL-8 gene and protein expression in
cells exposed to hyperglycemia. As compared with the
5-mM glucose control treatment on day 1, DMVECs co-
treated with 100 nM SP demonstrate statistically significant
decreases in IL-8 gene expression (5 mM glucose [1.000 
0.000] vs 5mMglucose 100 nMSP [0.654 0.051], n
3; P .01). As compared with the 30 mM glucose treatment
on day 7, DMVECs cotreated with 100 nM SP demonstrate
statistically significant decreases in IL-8 gene expression (30
mM glucose [1.000 0.000] vs 30 mM glucose 100 nM
SP [0.391 0.167], n 3, P .001; Fig 4, A).
Furthermore, compared with 5-mM, 10-mM, or
30-mM glucose treatments on day 7, DMVECs cotreated
with 100 nM SP demonstrate statistically significant de-
creases in IL-8 protein expression (5 mM glucose [0.102
0.013] vs 5 mM glucose  100 nM SP [0.069  0.015],
n  3; P  .001; 10 mM glucose [0.084  0.005] vs 10
mM glucose  100 nM SP [0.054  0.009], n  3; P 
.001; 30 mM glucose [0.108  0.014] vs 30 mM glucose
 100 nM SP [0.037 0.010], n 3; P .001; Fig 4, B).
DMVECs treated with NPY 100 nM demonstrate no
significant differences in IL-8 gene or protein expression at
days 1 or 7 (Fig 4, A and B).
IL-8 cotreatment does not affect DMVEC prolifera-
tion or tube formation in cells exposed to hyperglycemia.
DMVECs cotreated with 10 ng/mL IL-8 do not demon-
strate any statistically significant changes in proliferation (Fig
Fig 2. Effect of substance P (SP) cotreatment on derm
tube formation. A, Effect of 5 mM, 10 mM, and 30 m
proliferation at 1, 2, 3, 5, and 7 days. Data represente
respectively (n  3, mean  SD; **P  .01, ***P 
treatment with 5 mM or 30 mM glucose and cotreatm
fluorescent tubes normalized to total well area (n  3, m5, A) or tube formation (Fig 5, B and Supplemental Fig 1, nnline only) at any glucose concentrations. However, similar
o NPY, a trend toward increased tube formation with IL-8
otreatment in both the 5-mM glucose and 30-mM glucose
oncentrations is observed (Fig 5, B).
ISCUSSION
This study delineates the effects of neuropeptides on
MVEC proliferation, tube formation, and cytokine ex-
ression associated with normal and hyperglycemic condi-
ions. Diabetes is associated with a high incidence of neu-
opathy and altered neuropeptide function. Accordingly,
esearch has brought attention to the dysregulation of
europeptides and cytokines in wound healing in diabetes.
MVECs are fundamental to the wound healing process,
ut research on the effects of hyperglycemic conditions and
europeptides on these cells is limited. Thus, the identifi-
ation of the effects of neuropeptides and cytokines on
MVECs, is essential to the development of viable treat-
ent options for impaired wound healing in diabetes.
Previous research has demonstrated that diabetes
auses a chronic inflammatory state in which the expression
f cytokines is significantly increased and that this chronic
nflammatory state disrupts the wound healing process.4,7
n other disease models, SP is known to increase the
xpression of IL-8, a known autocrine, proangiogenic
arker, and hence, it was logical to investigate the effects of
P on IL-8 expression in DMVECs. NPY, on the other
and, is known to be proangiogenic, but the exact mecha-
rovascular endothelial cell (DMVEC) proliferation and
lucose and cotreatment with 100 nM SP on DMVEC
relative OD compared to day 1 for each treatment,
). B, Quantification of DMVEC tube formation upon
ith 100 nM SP. Data are represented as area of intact
SD; *P  .05, ***P  .001).al mic
M g
d as
.001
ent wism by which it exerts its effect is not known.
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June 20111658 Jain et alIn the present study, although hyperglycemic conditions
caused significant decreases inDMVECproliferation and tube
formation, they did not change IL-8 expression (Supplemen-
tal Fig 2, online only). This suggests that the impairment of
DMVEC proliferation and tube formation in hyperglycemic
conditions is not related to a dysregulation of cytokine expres-
sion by DMVECs but an impairment of other processes in
endothelial cells. Furthermore, it appears that DMVECs do
not contribute to the chronic inflammatory state in diabetes
through the upregulation of cytokine expression. As only one
cytokine out of the numerous cytokines involved in inflamma-
tion is studied, this effect could be exclusive to IL-8 expression
byDMVECs, and further studieswould need tobe performed
to observe the effects of a hyperglycemic environment on the
expression of other inflammatory cytokines by DMVECs.
Still, given that IL-8 is a key inflammatory cytokine, it is
unlikely that other cytokines would be affected while IL-8
expression is not. These findings have implications for further
studies of cellular processes in endothelial cells that are affected
in diabetes.
Here, we found that SP significantly increased DMVEC
proliferation and tube formation in hyperglycemic conditions.
This correlated with a decrease in IL-8 gene and protein
expression in the hyperglycemic conditions. It is important to
note that in normoglycemic conditions, there is an initial
decrease in IL-8 gene expression with SP cotreatment at day
1, which is not sustained at the day 7 time point. On the other
hand, the protein expression in the same treatment group is
Fig 3. Effect of neuropeptide Y (NPY) cotreatment on
and tube formation. A, Effect of 5 mM, 10 mM, and 30 m
proliferation at 1, 2, 3, 5, and 7 days. Data represente
respectively (n 3, mean SD). B,Quantification of DM
glucose and cotreatment with 100 nM NPY. Data repre
well area (n  3, mean  SD; ***P  .001, NS  not sunchanged at day 1 time point but decreased at day 7 time coint.One reason for this could be that SP acutely affects IL-8
ene expression, but these effects are not immediately trans-
ated into protein expression. However, with sustained SP
otreatment, an effect on protein expression is eventually
bserved. Thus, as with other important proteins, there is
otentially a lag period between changes in gene expression
nd subsequent protein translation. Also, there could be a
ebound effect on gene expression after the initial decrease
bserved, which could explain the normalization of gene
xpression at the day-7 time point. Future studies will include
arlier time points (2, 6, and 18 hours) and also intermediary
oints (36, 48, and 72 hours) to obtain a complete picture of
P’s regulation of IL-8 in DMVECs.
Furthermore, distinct dose-response trends following SP
reatment, in which increased proliferative response and de-
reased IL-8 protein expression with increased glucose con-
entrations were identified. These findings demonstrate that
P modulates IL-8 expression in DMVECs. However, since
L-8 cotreatment did not influence proliferation or tube for-
ationofDMVECs, it is evident that althoughSP affects IL-8
xpression, SP does not affect DMVEC angiogenic function
hrough IL-8. Moreover, the protein expression of the SP
eceptor, NK1R, was not altered by hyperglycemia (data not
hown). Thus, the mechanism of SP’s effects on DMVECs is
nclear, and further studies into the signaling processes re-
ated to these effects are warranted.
As opposed to SP, NPY did not promote DMVEC
roliferation or tube formation in normal or hyperglycemic
al microvascular endothelial cell (DMVEC) proliferation
lucose and cotreatment with 100 nMNPY on DMVEC
relative OD compared to day 1 for each treatment,
C tube formation upon treatment with 5 mM or 30 mM
d as area of intact fluorescent tubes normalized to total
cant).derm
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senteonditions, with no dose-response trend related to glucose
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Volume 53, Number 6 Jain et al 1659concentration identified. Given that other studies have
found that NPY induces human umbilical vein endothelial
cell migration, proliferation, and tube formation, our re-
sults indicate that DMVECs are unlike other types of
endothelial cells and that NPY could affect other cellular
processes.16 Additional research demonstrates that the pro-
tein expression of one of theNPY receptors, NPY5R, which
is related to the angiogenic function of NPY, was not
altered by hyperglycemia (data not shown), which lends
support to the conclusion that changes in glucose concen-
tration did not influence treatment outcomes in this study,
and that NPY could affect other processes in these cells.
The fact that NPY did not affect DMVEC IL-8 expression
further attests to the fact that IL-8 is not involved in the
pathways by which DMVEC proliferation and tube forma-
tion are promoted.
We observed that DMVEC proliferation continued
over the 7-day period studied, with proliferative activity
increasing over time and significant differences in prolifer-
ation identified by day 7. Moreover, with most treatment
conditions, significant differences in IL-8 gene or protein
expression, which were not present on day 1 were established
by day 7. In normal wound healing, the proliferative phase,
ultimately resulting in angiogenesis and re-epithelialization,
begins about 3 days following injury, peaks about 7 days
following injury, and is marked by the migration and prolifer-
ation of endothelial cells, keratinocytes, fibroblasts, and
Fig 4. Effect of substance P (SP) or neuropeptide Y (N
expression.A, Effect of 5 mM, 10mM, and 30mM gluco
gene expression at 1 and 7 days. Data expressed as fold
30-mM glucose control treatments, respectively (n 3,
B, Effect of 5 mM, 10 mM, and 30 mM glucose and co
expression at 1 and 7 days. Data normalized to total proother cell types.2,9 Thus, the increasing proliferative activity rbserved in the DMVECs over time, as well as the results
bserved on day 7 following treatment, imply a possible
echanism related to wound healing in which endothelial
ells require longer exposure to the wound microenviron-
ent before significant effects are detected.
The aim of this study was to characterize the effects of
europeptides and cytokines on DMVECs in normal and
yperglycemic conditions. It is understood that there are
imitations with research on wound biology with in vitro
onditions. The complete wound microenvironment can-
ot be accurately simulated, and hence, a thorough evalu-
tion of the complex molecular signaling and interaction
nvolved in wound healing is restricted. Nevertheless, iden-
ifying the mechanisms underlying the effects of these
europeptides and cytokines provides a basis from which to
uide the development of potential therapeutics for im-
aired wound healing in diabetes.
Further studies are warranted to investigate the effects
f SP on other known effectors of angiogenesis, such
ngiopoietins and other cytokines, in DMVECs using mul-
iplex assays. Finally, understanding the effects of NPY and
P on inflammatory cell cytokine expression will be impor-
ant in characterizing other contributors to the wound
icroenvironment and possible causes of impaired wound
ealing in diabetes.
In conclusion, this study demonstrates impairedDMVEC
roliferation and tube formation in hyperglycemic envi-
cotreatment on interleukin-8 (IL-8) gene and protein
d cotreatment with 100 nM SP or 100 nMNPY on IL-8
ge in gene expression compared to 5-mM, 10-mM, or
 SD; **P .01, ***P .001, NS not significant).
ent with 100 nM SP or 100 nM NPY on IL-8 protein
n  3, mean  SD; ***P  .001).PY)
se an
chan
mean
treatmonments, which is not associated with a change in
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June 20111660 Jain et alDMVEC IL-8 expression. Furthermore, we demonstrate
increased DMVEC proliferation and tube formation with
SP treatment, which does not appear to be associated with
decreased DMVEC IL-8 expression. Overall, we identify
SP as a potential therapeutic target for the promotion of the
angiogenesis phase of wound healing, and future studies
are warranted to further define the interplay between neu-
ropeptides and inflammatory cytokines in diabetes.
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